Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
1 2 3 ... 31 32 33 ... 54 55 56

Deal: Collaboration or Financing	Date
Roche–Activiomics: mass spectrometry services, 201309 supply services recent partner is Genentech	2013-09-30
Analytik Jena–Endress+Hauser: investment, 201309–201603 mandatory offer for remaining 52.67% of shares for €13.75/share	2013-09-27
Analytik Jena–PERSON: investment, 201309 existent founder + CEO Klaus Berka owns 9.93%	2013-09-27
Panasonic–Kohlberg Kravis Roberts: investment, 201309– acquisition $1.67b of 80% share in Panasonic Healthcare Co Ltd by KKR	2013-09-27
Merck (DE)–Ablynx: Nanobodies, 201309– collab co-discovery + co-developm Nanobodies extension Merck Serono	2013-09-26
Panoptes Pharma–4SC: investment, 201309 4SC Discovery receives 24.9% share in Panoptics as part of license for PP-001	2013-09-26
Panoptes Pharma–4SC: PP-001, 201309– license for inflammatory eye diseases against 24.9% share in Panoptes plus milestones + royalties	2013-09-26
Panoptes Pharma–SEVERAL: investment, 201309 seed financing round €1.2m from aws-Life Science Austria + private investors	2013-09-26
Indivumed–Sysmex: investment, 201309–201310 acquisition of 100% of Inostics GmbH + its subsidiary Inostics Inc by Sysmex Corp	2013-09-25
Roche–Pacific Biosciences: SMRT technology, 201309– collab ww excl $35m upfront developm + manufacture products for clinical use for Roche Diagnostics	2013-09-25
Partec–Sysmex: investment, 201309 acquisition of Partec GmbH by Sysmex Corp	2013-09-24
Myelo Therapeutics–Berlin (govt): investment, 201309 financing round Series A incl VC Fonds Technologie Berlin	2013-09-23
Myelo Therapeutics–Eckert Wagniskapital: investment, 201309 financing round Series A incl Eckert Wagniskapital und Frühphasenfinanzierung GmbH	2013-09-23
Myelo Therapeutics–JSC Valenta Pharmaceuticals: investment, 201309 financing round Series A incl JSC Valenta Pharmaceuticals	2013-09-23
Myelo Therapeutics–SEVERAL: investment, 201309 financing round Series A from VC Fonds Technologie Berlin + Eckert Wagniskapital + JSC Valenta	2013-09-23
Verenium–BASF: investment, 201309–201310 acquisition $52m cash tender offer $4/share by BASF Corporation	2013-09-20
Bruker–Philips: magnetic particle imaging, 201309 collab co-developm + co-marketing of preclinical MPI system	2013-09-19
Kyowa Hakko Kirin–Activiomics: mass spectrometry services, 201309– supply extension research services w TIQUAS technology within BioFocus partnership	2013-09-19
IKFE–Columbia Healthcare Services: investment, 201309 acquisition 100% of IKFE Services GmbH which continues business of bankrupt IKFE Institut	2013-09-18
MorphoSys–SEVERAL: investment, 201309 private placement €84m with 1.5m new shares €55.76/share to institutional investors	2013-09-18
Evonik–Genedata: bioinformatics, 201309– collab expansion use of integrated Genedata offering incl Genedata Selector	2013-09-17
Microstim–SEVERAL: investment, 201309 financing round €500k MVP + HTGF + Fides Finanz-Invest	2013-09-17
Affimed–MC Services: public relations, 201309 service existent for Affimed Therapeutics AG	2013-09-16
Bruker Corp–Siscapa: SISCAPA assay technology, 201309– collab extension developm SISCAPA-MALDI workflows + installation in demo facility	2013-09-16
Rhön-Klinikum–Fresenius: investment, 201309– acquisition of 43 German hospitals for €3.07b by Fresenius Helios ANNOUNCED	2013-09-13
Evotec–Harvard Univ: drug discovery, 201309– collab €na drug discovery for ALS using iPS cells with HSCI	2013-09-12
Prairie Technologies–Bruker Corp: investment, 201309 acquisition by Bruker	2013-09-12
Bayer–MIT: personalised cancer drugs, 201309– collab 5y discovery + development using oncogenomics with Broad Institute	2013-09-10
Bruker Corp–Peak Scientific: gas generator, 201309– supply OEM excl for Bruker GC-MS range + supporting for LC-MS	2013-09-10
Roche–Inovio: therapeutic vaccines, 201310– license ww excl $10m upfront + $412.5m milestones for INO-5150 + INO-1080 + use of Cellectra technology	2013-09-10
Neurodyn–Galantos: galantamine, 201309 acquisition of all assets related to Memogain® formulation of galantamine by Neurodyn	2013-09-09
ArcherDX–Enzymatics: investment, 201309 acquisition up to $50m in cash + equity + milestones	2013-09-06
Novartis–Regenerex: cell therapy, 201309– global license + research collab for use of hematopoietic stem-cell based FCRx platform	2013-09-06
Wilex–Nuclea Biotechnologies: investment, 201309 acquisition 100% of Wilex Inc by Nuclea w repayment $2.5m interfirm loan + $2.5m services + royalties	2013-09-06
Debiopharm–Go To Market: business consulting, 201309– supply service identification of early-stage in-licensing opportunities on US West Coast	2013-09-05
Piqur Therapeutics–SEVERAL: investment, 201309 private placement (third seed financing round)	2013-09-05
Analytik Jena–Endress+Hauser: investment, 201309 capital increase €24.4m incl Endress+Hauser with resulting direct + indirect 47.33% share for E+H	2013-09-04
Analytik Jena–SEVERAL: investment, 201309 capital increase €24.4m €23.4m net 1.95m new shares €12.5/share exlusively to existent shareholders	2013-09-04
AstraZeneca–Genedata: bioinformatics, 201309 license existent AstraZeneca using Genedata Screener s/w	2013-09-04
Lilly–Genedata: bioinformatics, 201309 license existent Eli Lilly using Genedata Screener s/w	2013-09-04
Perora–High-Tech Gründerfonds: investment, 201309 seed financing round led by HTGF	2013-09-04
Vertex–Genedata: bioinformatics, 201309 license existent Vertex Pharmaceuticals using Genedata Screener s/w	2013-09-04
Arsanis–Adimab: therapeutic antibodies, 201309 collab development human MAbs for serious infectious diseases	2013-09-03
Arsanis–SEVERAL: investment, 201309 financing round Series B $20m led by NeoMed Management	2013-09-03
BioFire Diagnostics–Mérieux: investment, 201309–201401 acquisition 100% for $540m in cash by bioMérieux	2013-09-03
Boehringer–Diaxonhit: drug discovery services, 201309– supply service €na discovery of oncology drug targets using SpliceArray platform	2013-09-03
Horizon Discovery–Sigma-Aldrich: DNA-editing technology, 201309– license non-excl €na use of CompoZr ZFN techn tog w rAAV techn under GENESIS brand	2013-09-03
Leukocare–SEVERAL: investment, 201309 capital increase €3.4m incl conversion of €1m corporate bond from new + existing investors	2013-09-03
DIAGMAL project–EU (govt): grant, 201309–201608 FP7 grant €2.652m out of total project cost of €3.556m	2013-09-01
EpimiRNA project–Bicoll: drug discovery technology, 201309–201808 Bicoll is project partner using its Profiles technology for drug discovery	2013-09-01
EpimiRNA project–EU (govt): grant, 201309–201808 FP7 Grant €11.5m	2013-09-01
HEPAVAC project–EU (govt): grant, 201309–201808 FP7 grant €6m to develop vaccine for hepatocellular carcinoma	2013-09-01
Q-Bioanalytic–EU (govt): grant, 201309–201608 FP7 grant €670k as member of DIAGMAL project	2013-09-01
Sartorius–SEVERAL: credit, 201309– syndicated €250m 5-year loan to SSB from bank syndicate led by Commerzbank + Nord/LB	2013-09-01
Evotec–BVF Partners: investment, 201308 capital increase €30m 11.8m new shares €2.55/share to Biotechnology Value Fund LP	2013-08-31
Technical Univ Denmark–Thermo Fisher: mass spectrometer, 201308 supply four Q Exactive LC-MS/MS + nano-LC 1000 systems to Dept of Systems Biology	2013-08-30
Technical Univ Denmark–Thermo Fisher: mass spectrometer, 201308 supply one Oribtrap Fusion Tribrid system to Dept of Systems Biology	2013-08-30
Thermo Fisher–Technical Univ Denmark: mass spectrometry, 201308– collab developm new proteomic applications with Dept of Systems Biology at DTU	2013-08-30
Genfit–Bicoll: drug discovery technology, 201308 collab existent using Bicoll’s Profiles technology for target identification	2013-08-29
ObsEva–SEVERAL: investment, 201309 financing round Series A CHF32m (€25.6m) led by Sofinnova Partners	2013-08-29
Argos–Pharmstandard: investment, 201308 financing round Series E totalling $42.5m incl $30m from Pharmstandard receiving Russian sales rights	2013-08-26
Argos–SEVERAL: investment, 201308 financing round Series E $42.5m led by Pharmstandard who received Russian commercialisation rights	2013-08-26
Life Technologies–PIKA Weihenstephan: molecular food testing, 201308– distribution of PIKA’s Fast Orange Nutrient + PCR tests for brewing + beverages	2013-08-26
Onyx–Amgen: investment, 201308–201310 acquisition $10.4b in cash $125/share	2013-08-25
CLC bio–Qiagen: investment, 201308 acquisition by Qiagen	2013-08-22
Omnilab (DE)–Serva Electrophoresis: electrophoresis, 201308– distribution of Serva products + reagents by Onmilab	2013-08-22
Helmholtz–NN: mass spectrometer, 201308 supply existent use of SIMS at HZDR in Dresden	2013-08-21
Helmholtz–NN: mass spectrometer, 201308 supply installation of €3.6m SIMS at GeoForschungsZentrum Potsdam	2013-08-21
Epigenomics–Yorkville Group: investment, 201308– standby equity line up to $5m convertible bonds to be purchased 2y by YA Global Master SPV on request	2013-08-19
China Medical City–Boehringer: animal vaccine, 201308– collab joint venture for €58m manufacturing plant at China Medical City in Taizhou	2013-08-16
Eppendorf–Manufactus: manufacturing software, 201308– supply use of eKanban System IKS by Eppendorf Liquid Handling GmbH	2013-08-16
PP Wealth–SEVERAL: investment, 201308– private placement up to €32.5m of Valeado GmbH & Co KG set up by Lead Discovery Center + PP Wealth GmbH	2013-08-16
CAP-CMV GmbH–SEVERAL: investment, 201308–201403 seed/startup financing rounds €1.7m by PVP + NRW.Bank + Creathor Venture + KfW + private investors	2013-08-12
Syngenta–Caprotec: CCMS technology, 201307– supply service €na profiling interactions of new active ingredients with proteome for Syngenta	2013-08-12
Addex–SEVERAL: investment, 201308 private placement CHF3.2m ($3.5m) net CHF3.1m 1.17m new shares CHF2.75/share to institutional investors	2013-08-09
Ixchelsis–TVM: investment, 201308 investment in start-up Ixchelsis Ltd by TVM Life Science Ventures VII	2013-08-06
Bayer–Compugen: cancer immunotherapy, 201308– collab r+d + ww excl license $10m upfront + $530m milestones + royalties against 2 targets	2013-08-05
Danone–Eurofins: food analysis, 201308– supply food testing service at least €30m revenue over 5y by newly acquired CLF	2013-08-02
Danone–Eurofins: investment, 201308 acquisition of Central Laboratories Friedichsdorf (in-house Milupa lab) by Eurofins	2013-08-02
Exelonix–High-Tech Gründerfonds: investment, 201308 seed financing from HTGF	2013-08-02
Apeiron–Rentschler: biological contract manufacturing, 201308– production + supply of APN311 for clinical studies + market	2013-08-01
Axa–Klocke: investment, 201308–201311 acquisition €na of Animal Health div of Riemser Pharma GmbH + production facility in Riems by IDT Biologika	2013-08-01
CorTec–High-Tech Gründerfonds: investment, 201308 existent HTGF is investor in CorTec GmbH	2013-08-01
E-HOD project–EU (govt): grant, 201308– grant €1.15m over 3 years	2013-08-01
Ferrero–Biotecon: real-time PCR food safety tests, 201308 supply existent Ferroro is among customers	2013-08-01
Lindt & Sprüngli–Biotecon: real-time PCR food safety tests, 201308 supply existent Lindt & Sprüngli is among customers	2013-08-01
SCOPE-DMD project–EU (govt): grant, 201308– FP7 grant €6m over 3 years	2013-08-01
Ceptaris Therapeutics–Actelion: investment, 201307–201309 acquisition $250m in cash + milestones	2013-07-31
NovaPump–High-Tech Gründerfonds: investment, 201307 1st financing round with HTGF	2013-07-31
Capical–SEVERAL: investment, 201307 financing Series A from M-Invest + KfW	2013-07-30
Novartis–Adimab: antibody technology, 201307 collab existent w regard to Adimab antibody discovery platform	2013-07-26
Novo Nordisk–Adimab: antibody technology, 201307 collab existent w regard to Adimab antibody discovery platform	2013-07-26
Roche–Adimab: antibody technology, 201307 collab existent w regard to Adimab antibody discovery platform	2013-07-26
Noxxon–College Group: public relations, 201307 service existent by College Hill Life Sciences	2013-07-24
CorTec–SEVERAL: investment, 201307 2nd financing round €3m incl new investors M-Invest + KfW	2013-07-23
JenaValve–SEVERAL: investment, 201307 financing round Series C $62.5m led by Gimv	2013-07-23
Poonawalla–Deutsche Stiftung Impfstoffforschung: tuberculosis vaccine, 201307– acquisition of rights to VPM1002 by Serum Institute of India from VPM	2013-07-23
Qiagen–Exosome Diagnostics: nucleic acid sample preparation, 201307– collab excl €na developm + commerc sample prep kits for NA from exosomes	2013-07-23
Bayer–Caprotec: CCMS technology, 201307– supply service €na profiling interactions of new active ingredients for 2nd target of Bayer CropScience	2013-07-22
Caprotec–College Group: public relations, 201307 service existent by College Hill Life Sciences	2013-07-22

1 2 3 ... 31 32 33 ... 54 55 56

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Advertise

Deals > All